Internet Explorer 8 Warnung Anscheinend verwenden Sie einen älteren Internet Explorer. Leider unterstützen wir, genau wie Microsoft, diesen Browser nicht mehr. Sie werden also Fehlermeldungen und ein inkonsistentes Design erleben.
Bitte haben Sie Verständnis und entschuldigen Sie die Unannehmlichkeiten.

Portfolio Finder

Current Startups


Lipocalyx provides leapfrog innovation for genetic research. Our Viromers® deliver the bits and pieces of DNA or RNA necessary to interfere with the genetic content of a cell. Viromers® take advantage of a viral fusion mechanism and, for the first time, translate this into polymer chemistry. As a result, we can reach into hard-to-transfect cells and enable siRNA or plasmid work there.

Lipocalyx started its marketing in Jan 2013 and announced a global network of distributors in Sep 2014.
Challenge:          Transfection of resistant cells

Solution:             Viromers, polymers using an Active Escape Technology

Business:            Reagent provider & know-how provider around transfection, direct and distributor sales, co-developments

Technology:       Active Endosome Escape for superior tranfection,

IP:                        Umbrella patent for Viromers, specific IP for products, trademarks

Market:               Transfection market $283M, market potential for Viromers $80M

Customers:        R&D in academia and industry, in particular those working with resistant or sensitive cells like primary cells or stem cells

Geography:        Global Distribution

Competition:     Life Technologies, offereing a one-stop solution for both siRNA and transfection is the most dominant player; strong brands, e.g.Fugene by Promega; electroporation (Lonza, BioRad) is currently used for resistant cells. Works well for plasmids, but not for siRNA.

Cell penetrating peptides may come up as competition ; in the future „downgrading“ of in vivo reagents may become a competition

Info & Contact


Weinbergweg 23
06120 Halle (Saale)

Added to portfolio

14. Jul 2011